MEET McLAREN

AI-ENABLED INCIDENTAL CARDIOVASCULAR SCREENING



McLaren Heart and Vascular Institute (MHVI) is expanding cardiovascular risk detection through an AI-enabled screening program that identifies clinically significant cardiac and vascular findings from routine chest CT imaging previously performed for other medical reasons.

In partnership with Bunkerhill Health and its FDA-cleared Carebricks platform, MHVI applies validated algorithms to chest CT scans performed for non-cardiac indications.

The technology detects and quantifies:

- Incidental Coronary Artery Calcium (iCAC)
- Incidental Aortic Valve Calcium (iAVC)
- Abdominal Aortic Aneurysm (AAA)

These findings are established markers of coronary artery disease, aortic stenosis, and aneurysm risk – conditions that often progress silently until advanced.

Because this assessment leverages existing chest CT imaging (e.g., lung cancer screening, infection evaluation, trauma, or other thoracic indications), looking back one year, the program expands cardiovascular risk identification without additional imaging, radiation exposure, or patient scheduling.

McLaren
HEART & VASCULAR INSTITUTE

CLINICAL VALUE

- Opportunistic cardiovascular risk detection
- Earlier identification of subclinical disease
- No additional testing required
- Supports preventive cardiology referral and management

REFERRAL PATHWAY

Providers receiving elevated iCAC, iAVC, or AAA findings may refer patients directly to McLaren cardiology.

Orders can be faxed or sent directly from Cerner.

A complete cardiology directory is available at **mclaren.org/heartdoc**

If you have any questions, contact McLaren Heart and Vascular Institute Patient Navigator Tonya Smith at (810) 342-4699.

Care coordination and referral resources are available at mclaren.org/careconnect